KKR, a global investment firm, and Bushu Pharmaceuticals Ltd. have signed a definitive agreement under which KKR will acquire all shares in Bushu Pharma from BPEA EQT.
Following the transaction’s completion, KKR aims to accelerate Bushu Pharma’s growth and further position the company as a leading contract development and manufacturing organization (CDMO) for the pharmaceuticals market in Japan and worldwide.
